Abstract: Pemphigus vulgaris (PV) is the most common type of pemphigus. Rituximab has been recommended as first-line therapy in foreign guidelines, but in our country it is recommended as second-line therapy for moderate to severe PV. With the further study of the pathogenesis of PV, some new therapeutic targets have been found that may play a role in the treatment of PV, for example, new biological agents, inhibitors of B-cell activating factor and proliferation-inducing ligand, T-cell immunotherapy, JAK inhibitors, etc. , will provide more treatment options for the clinics.

Key words: pemphigus vulgaris, anti-CD20 monoclonal antibody, B cell activator, proliferation-induced ligand, T-cell immunity, JAK inhibitor